BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1 CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and … [Read more…]
